Tuhura Biosciences, Inc.
Clinical trials sponsored by Tuhura Biosciences, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental tumor injection aims to supercharge immunotherapy in rare skin cancer Results expected Mar 2027 (estimated)
-
Experimental tumor injection aims to supercharge immunotherapy in rare skin cancer
Disease control Recruiting nowThis study tests whether adding an experimental drug called IFx-Hu2.0 (injected directly into a tumor) to the standard immunotherapy pembrolizumab can improve outcomes for people with advanced or metastatic Merkel cell carcinoma. About 118 adults who have not received checkpoint …
Phase 2/3 • Sponsor: TuHURA Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Experimental combo therapy targets Hard-to-Treat skin cancer
Disease control Recruiting nowThis early study tests a new cancer vaccine called IFx-Hu2.0 given together with the immunotherapy drug pembrolizumab (Keytruda) in 9 adults with advanced or metastatic Merkel cell carcinoma. The vaccine is injected directly into a tumor, and pembrolizumab is given through an IV.…
Phase 1 • Sponsor: TuHURA Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC